Full-Time

QA Shop Floor Specialist 2/3

Posted on 9/23/2025

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Compensation Overview

$76k - $99.7k/yr

Bridgewater Township, NJ, USA

In Person

Category
QA & Testing (1)
Required Skills
SAP Products
Excel/Numbers/Sheets
Requirements
  • Bachelors degree required in Life Sciences or Engineering.
  • 0-2+ years Biotech/Pharmaceutical experience or equivalent industry experience
  • Must have relevant working experience in an aseptic manufacturing facility, preferably in quality assurance, manufacturing compliance, clinical quality, technical operations or cell therapy.
  • Experience with quality support in clinical manufacture is preferred.
  • Flexible to work on weekends, as needed.
  • Needs to be mobile and able to independently transport themselves between various sites/locations, as dictated by the essential functions and responsibilities of the position.
  • Is frequently required to communicate with coworkers.
  • While performing the duties of this job, the employee is regularly required to stand; walk; climb, bend and stoop; and reach with hands and arms.
  • Ability to lift 20 lbs.
  • Report to work on-time.
  • Duties are required to be performed on-site at manufacturing facility.
  • Perform other duties as assigned.
  • Attend departmental and other scheduled meetings.
  • Practice good interpersonal and communication skills.
  • Demonstrate positive team-oriented approach in the daily execution of procedures.
  • Promote and work within a team environment.
  • Learn new skills, procedures and processes as assigned by management and continue to develop professionally.
  • Support and contributes to projects.
  • Assist in troubleshooting issues related to manufacturing.
  • Technical knowledge within functional units
  • Demonstrate an understanding of the process in order to properly perform the assigned tasks.
  • Strong proficiency utilizing relevant manufacturing applications (SAP), electronic batch records (EBR), and quality systems.
  • Utilizes tools within MS Office and other systems to improve business effectiveness.
  • Read and interpret documents such as safety rules, operating instructions, and logbooks.
  • Review and provide feedback for SOPs.
  • Interpret a variety of instructions furnished in written, oral, or diagram.
  • Ability to deal with complexity across the drug product, the associated manufacturing process, and the end-to-end supply chain process.
  • Solve practical problems and deal with a variety of concrete variables in situations where only limited standardization exists.
  • Add, subtract, multiply and divide in all units of measure, using whole numbers, common factions, and decimals,
  • Aseptic processing in ISO 5 clean room and biosafety cabinets.
  • Knowledge of cGMP regulations and FDA/EU guidance related to manufacturing of cell-based products as well as knowledge of Good Tissue Practices.
  • Great attention to detail and ability to follow the procedures.
  • The candidate must be highly organized and capable of working in a team environment with a positive attitude under minimal supervision.
  • Good written and verbal communication skills are required.
  • Ability to summarize and present results, and experience with team-based collaborations is a must.
  • Must be able to interpret problems and effectively determine appropriate resolutions that ensure compliance and minimize risk.
  • Ability to collaborate well with stakeholders, customers and peers.
  • Must exhibit strong decision-making ability and think creatively while maintaining compliance and quality.
  • Must be able to discern the criticality of issues and to communicate to management regarding complex issues.
  • Ability to manage conflict and issues that arise with internal or external customers.
Responsibilities
  • Provide Quality oversight of all aspects of the cell therapy clinical manufacturing process.
  • Support manufacturing activities for cGMP compliance through spot checks/internal audits.
  • Collaborate with site personnel to provide guidance and determine immediate path forward for manufacturing quality issues.
  • Review of all documentation, in accordance with Good Documentation Practices (GDP).
  • Review, revise, or draft Standard Operating Procedures (SOPs)
  • Support processes that include aseptic process simulations, Commercial & clinical manufacturing, miscellaneous runs that are conducted to support manufacturing to ensure sterility of the product/process is not compromised.
  • Support batch review & material release in SAP for In-house reagents.
  • Support Floor Spot-check, audit trail review.
  • Strive to reduce non-conformances in supported areas by proactively driving compliance.
  • Support Investigations team by providing quality and compliance input for continuous improvement and remediations.
  • Serve as a backup for approving printed labels and documents prior to use on the manufacturing floor.
  • Utilize multiple electronic quality systems, batch records and SAP.
  • Work in a team based, cross-functional environment to complete tasks required to meet business objectives.
  • Must be able to aseptically gown to Support Grade B Clean rooms / practice aseptic behavior in controlled areas.
  • Provide QA shop floor support for extended periods of time.
  • Responsibilities will include but not limited to tasks mentioned above.
  • Support regulatory inspections and audits as needed.
  • Consistently perform tasks in adherence with safety policies, quality systems, and cGMP requirements, as well as according to state and federal regulatory requirements.
  • Other duties will be assigned, as the need arises.
  • Job duties performed routinely require exposure to and handling of biological materials and hazardous chemicals.
  • Distance visual acuity of at least 20/30 (Snellen) in both eyes without corrective lenses or visual acuity corrected to 20/30 (Snellen) or better with corrective lenses
  • Color Perception both eyes 5 slides out of 8.
  • Works in a collaborative team setting with quality counterparts that include Manufacturing Operations, Operations Technical Support, Maintenance, Supply Chain and Planning

Legend Biotech develops and commercializes cell therapies for serious diseases, including hematologic cancers and solid tumors, with a focus on personalized medicine. Its therapies, like CAR-T treatments, work by collecting a patient’s cells, engineering them to target cancer cells, expanding them, and reinfusing them into the patient. The company differentiates itself by using multiple technology platforms (technology-agnostic) and pursuing a broad pipeline, including exclusive global licenses for CAR-T therapies. Its goal is to bring effective, personalized cell therapies to market, improve outcomes for hard-to-treat cancers, and maintain transparent communication with investors while expanding globally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI generated about $597 million in Q1 2026 net trade sales.
  • LB2102 showed 28.6% response and 78.6% disease control in solid tumors.
  • Legend held $834.6 million in cash at March 31, 2026, funding pipeline expansion.

What critics are saying

  • CARVYKTI concentration makes revenue vulnerable to safety, pricing, or uptake shocks.
  • LB2102 remains early-stage, and solid-tumor CAR-T has a poor historical success rate.
  • Manufacturing or reimbursement setbacks can slow CARVYKTI expansion across 18 markets.

What makes Legend Biotech unique

  • Legend Biotech combines approved CARVYKTI revenue with early solid-tumor CAR-T programs.
  • The company develops autologous, allogeneic, CAR-NK, and gamma-delta T-cell platforms.
  • Legend runs a fully integrated cell-therapy platform spanning discovery, manufacturing, and commercialization.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Legend Biotech who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Mar 10th, 2026
Legend Biotech's CARVYKTI hits $555M Q4 sales, reaches profitability with 10,000-dose capacity

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in Q4, up 66% year-over-year. Management said CARVYKTI reached profitability in 2025 and expects enterprise-wide profitability in 2026. The therapy is now available in 14 global markets across 294 treatment sites. Legend has installed manufacturing capacity for 10,000 doses, with plans to expand to 20,000 alongside Johnson & Johnson. Manufacturing success rates range from 97% to 99%. Clinical data show median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines of therapy. Approximately 65% of patients are now treated in the second-to-fourth-line setting, reflecting earlier use in the treatment course. Legend ended 2025 with $949 million in cash and recorded adjusted net income of $2.5 million in Q4.

Yahoo Finance
Mar 10th, 2026
Legend Biotech reports $1.9B CARVYKTI sales for 2025, treats over 10,000 patients

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in the fourth quarter and $1.9 billion for the full year 2025, achieving franchise profitability. The company has treated over 10,000 patients with its CAR-T therapy and expanded availability to 294 sites across 14 markets worldwide. The company completed expansion of its Raritan facility, creating the largest cell therapy manufacturing site in the United States with capacity to support 10,000 patients annually. Legend Biotech also advanced its pipeline, opening a 31,000-square-foot R&D facility in Philadelphia and dosing the first patient for its in vivo candidates. As of 31 December 2025, Legend Biotech held $949 million in cash and cash equivalents, providing financial runway beyond 2026 when it expects to achieve company-wide operating profit.

Yahoo Finance
Feb 3rd, 2026
Legend Biotech shares drop 46% in 3 months despite $72 fair value estimate

Legend Biotech has raised $120 million in a Series C round led by Ribbit Capital, valuing the pre-revenue AI startup at $1.45 billion. Sequoia and Kleiner Perkins participated, alongside new backer Emerson Collective, bringing total capital raised to $295 million. Co-founded by Robinhood CEO Vlad Tenev, Harmonic develops "Mathematical Superintelligence" that eliminates AI hallucinations by requiring outputs in verifiable Lean4 programming code. Its Aristotle model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, the company currently offers Aristotle via free API to mathematicians and researchers. It plans future commercialisation targeting safety-critical sectors including aerospace, automotive and finance, where error-free logic is essential.

BioSpace
Jan 29th, 2026
Biotech's Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026

Biotech's next chapter: asset-centric deals and shifting alpha at JPM 2026. January 29, 2026 | After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation. Now that the sound and fury of the J.P. Morgan Healthcare Conference have subsided, investors are taking a step back to evaluate for 2026 the acquisition and capital environment, the buzzy therapeutic spaces and lingering risk factors. Biotech is emerging from a multiyear slump into a new cycle driven by fundamental progress and late-stage assets, said Roderick Wong, managing partner and chief investment officer at New York-based RTW Investments. Although JPM 2026 felt light on headline megadeals, record-setting M&A rumors before the conference around Revolution Medicines (reported to be in talks with Merck and AbbVie) and Abivax (with Eli Lilly speculation takeover) underscored strong demand for high quality, late-stage development assets, Wong said. Actual announced deals (e.g., Eli Lilly - Ventyx Biosciences, GlaxoSmithKline - RAPT Therapeutics, Boston Scientific - Penumbra) reinforced that asset-centric transactions are with clear blockbuster or strategic potential are the most interesting, Wong said. From RTW's vantage point and reinforced by several VC conversations on the sidelines of JPM26, asset-focused companies remain more attractive than pure platform or technology plays in the current environment. Hot therapeutic investment spaces. Key disease areas of focus include oncology (pancreatic, breast, bladder), where several programs could reset standards of care and address major unmet needs, noted Stephanie Sirota, partner and chief business officer at RTW. Obesity is another major theme, with anticipation around the first true small-molecule pill from Eli Lilly and a next wave of novel mechanisms, Wong said. One of RTW's portfolio companies, Corxel, announced on January 23 a $287 million Series D fundraising. Neuroscience/CNS has seen a sharp sentiment shift, with investors leaning back into space after years of limited innovation, Wong and Sirota agreed. Their comments echo those heard on the sidelines of JPM26; that advances in biomarkers, brain mapping and AI, as well as a rapidly aging population, support investment in the space. Psychedelics exemplify a potential paradigm shift in depression treatment modality, Wong said, with Compass Pathways' Phase III data and a possible near-term launch supporting nondaily, episodic treatment models. The cultural and medical shift in psychedelic therapeutic is one of the topics explored in the RTW's latest book "Innovation is the Best Medicine." FDA remains a risk factor. The degree of policy risk for the biopharma sector has declined significantly since the start of the Trump administration last year, Wong said. At the time, major uncertainties surrounded tariffs, manufacturing reshoring and Most Favored Nations drug pricing negotiations. What has evolved are reasonable resolutions that have been neutral to modestly negative rather than worstcase scenarios, he added. There have been many discussions around the chaotic year at the FDA in 2025, including a revolving door of senior staff members. The main remaining structural risk, Wong said, is FDA behavior in "edge cases," particularly in rare diseases and emerging modalities like gene and cell therapies, using nontraditional trial designs, surrogate endpoints or single arm studies. Last year's players in this space saw negative feedback or rejection, discussed in greater depth in the RTW book. RTW is responding by being more conservative around such edge case programs, which it expects will depress capital flows into some rare disease and early modality assets. Alpha stacking model. The firm frames its investment process as "alpha stacking:" starting with rigorous fundamental equity analysis (science underwriting plus commercial forecasting) and layering on multiple, evolving sources of information and assessment, Sirota said. This includes collecting information on policy, considering transactional and operational models, as well as what is compelling from a buyer perspective. The firm has built deep therapeutic specialization plus functional expertise (e.g., IP, geography such as China) to move beyond headline-driven views of risk and opportunity. RTW has also invested internally in data science, automation and AI to enhance its research process, they agreed. Ultimately, investment is always evolving, Wong said. He noted that a scientific background at one was the advantage - an alpha - one had when investing, but that's become understood. Rather, alpha stacking is now about intentionally trying to understand where the advantages lie and staying on top of these evolving factors. In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW's Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how "alpha stacking" shapes their investment edge in an age of chronic uncertainty. January 29, 2026

Stock Titan
Aug 18th, 2025
[6-K] Legend Biotech Corporation American Current Report (Foreign Issuer)

On August 18, 2025, Legend Biotech Corporation announced the appointment of Carlos Santos as the Company's Chief Financial Officer ("CFO").

INACTIVE